MGX (Metagenomi Therapeutics) Total Debt per Share: $1.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.19
GF Value $0.66
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Total Debt per Share?

Metagenomi Therapeutics MGX -1.65% 10 Total Debt per Share is $1.00 as of Jun. 2026. GuruFocus rates MGX with a GF Score™ of 10/100 and a GF Value™ of $0.66 (Significantly Overvalued). The stock has 4 warning signs investors should review.

$1.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Metagenomi Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 was $1.00.

Metagenomi Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Total Debt per Share Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
1.30 0.50 1.29 1.22 1.08

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.11 1.08 1.04 1.00
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Total Debt per Share Calculation

Metagenomi Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(34.63+6.03)/37.62
=1.08

Metagenomi Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(31.49+6.24)/37.78
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $1.00 mean?
Metagenomi Therapeutics (MGX) has a Total Debt per Share of $1.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Total Debt per Share too high?
Metagenomi Therapeutics' current Total Debt per Share is $1.00. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Total Debt per Share compare to BYSI and EXOZ?
Metagenomi Therapeutics' Total Debt per Share of $1.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Total Debt per Share is $1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.66, compared to a current price of $1.19 — trading 80.3% above its estimated fair value. The current Total Debt per Share is $1.00. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Total Debt per Share is $1.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metagenomi Therapeutics (MGX) Overvalued in 2026?

Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued. The current stock price of $1.19 is trading 80.3% above its estimated GF Value™ of $0.66. GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.

Key valuation signals for MGX:

  • Total Debt per Share: $1.00
  • GF Value™: $0.66 vs. price of $1.19 (80.3% above fair value)
  • GF Score™: 10/100 with 4 warning signs

No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price
$0.66
GF Value